Zobrazeno 1 - 10
of 117
pro vyhledávání: '"K. Vandervoort"'
Autor:
Margaret K. Vandervoort, Brian G. Feagan, Larry Stitt, Mark A Samaan, Carl A. J. Puylaert, Reena Khanna, Barrett G. Levesque, C. Y. Nio, Vipul Jairath, W J Sandborn, Guangyong Zou, G. D'Haens, Stuart A. Taylor, Jaap Stoker, Cynthia Santillan, Lisa M. Shackelton, Jordi Rimola, Pieter Hindryckx
Publikováno v:
Alimentary pharmacology & therapeutics, 46(5), 516-528. Wiley-Blackwell
SummaryBackground Magnetic resonance imaging (MRI) is the gold standard for assessment of perianal fistulising Crohn's disease (CD). The Van Assche index is the most commonly used MRI fistula index. Aims To assess the reliability of the Van Assche in
Autor:
Brian G. Feagan, Thomas P. Chapman, Lisa M. Shackelton, Daniël R. Hoekman, Majid A Almadi, Vipul Jairath, Mohammad Al Beshir, Elizabeth Minas, Sujata Biswas, Mark A Samaan, Simon Travis, Barrett G. Levesque, Claire E Parker, Reena Khanna, Geert D'Haens, Turki AlAmeel, Parambir S. Dulai, Nathan S. S. Atkinson, Andreas Koutsoumpas, Mahmoud Mosli, Talal Al-Taweel, Mark A. Glaire, William J. Sandborn, Guangyong Zou, Margaret K. Vandervoort, John K MacDonald
Publikováno v:
Journal of Crohn s & colitis. 10(5):607-618
BACKGROUND AN AIM: Minimization of the placebo responses in randomized controlled trials (RCTs) is essential for efficient evaluation of new interventions. Placebo rates have been high in ulcerative colitis (UC) clinical trials and factors influencin
Autor:
Alain Bitton, Margaret K. Vandervoort, Barrett G. Levesque, Guangyong Zou, Brian G. Feagan, Brian Bressler, Larry Stitt, Donald G. MacIntosh, Reena Khanna, Remo Panaccione, Geert R. D'Haens, Allan Donner, William J. Sandborn, Joan C. Morris, Gordon R. Greenberg, Severine Vermeire, Pierre Paré
Publikováno v:
Lancet, 386(10006), 1825-1834. Elsevier Limited
Summary Background Conventional management of Crohn's disease features incremental use of therapies. However, early combined immunosuppression (ECI), with a TNF antagonist and antimetabolite might be a more effective strategy. We compared the efficac
Autor:
Margaret K. Vandervoort, Guangyong Zou, Geert D'Haens, Reena Khanna, W J Sandborn, Larry Stitt, Brian G. Feagan, Barrett G. Levesque, Mahmoud Mosli, Vipul Jairath
Publikováno v:
Alimentary pharmacology & therapeutics, 42(10), 1200-1210. Wiley-Blackwell
SummaryBackground Patient-reported outcomes (PROs) have an increasingly important role in the evaluation of new therapies for inflammatory bowel disease. The US Food and Drug Administration has issued formal guidance to describe the role of PRO instr
Autor:
Brian G. Feagan, Cynthia Behling, Robert H. Riddell, Margaret K. Vandervoort, Rish K. Pai, Maida J. Sewitch, Michael R. Peterson, Cord Langner, Reena Khanna, Mark A. Valasek, William J. Sandborn, Larry Stitt, Kenneth A. Baker, Mark A Samaan, Barrett G. Levesque, David K. Driman, John K MacDonald, Guangyong Zou, Lisa M. Shackelton, Noam Harpaz, Keith J. Kaplan, Mahmoud Mosli, Geert D'Haens, Karel Geboes
Publikováno v:
Gut, 64(11), 1765-1773. BMJ Publishing Group
Objective Histopathology is potentially an important outcome measure in UC. Multiple histological disease activity (HA) indices, including the Geboes score (GS) and modified Riley score (MRS), have been developed; however, the operating properties of
Autor:
Margaret K. Vandervoort, Vipul Jairath, Rish K. Pai, D. Gilgen, G. D'Haens, Y. Marakhouski, E. Mikhailova, O. Levchenko, Pieter Hindryckx, Claire E Parker, Paul Rutgeerts, Larry Stitt, C. Muller, W J Sandborn, S. Pimanov, M. Horynski, N. Kharchenko, Guangyong Zou, Lisa M. Shackelton, Brian G. Feagan
Publikováno v:
Alimentary pharmacology & therapeutics, 46(3), 292-302. Wiley-Blackwell
SummaryBackground High concentration mesalazine formulations are more convenient than conventional low concentration formulations for the treatment of ulcerative colitis (UC). Aim To compare the efficacy and safety of 1600 mg and 400 mg tablet mesala
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b090c169aed889c12a45f669e15272c
https://pure.amc.nl/en/publications/randomised-noninferiority-trial-1600-mg-versus-400-mg-tablets-of-mesalazine-for-the-treatment-of-mildtomoderate-ulcerative-colitis(f5d69f28-c590-4b69-be55-44a95d2c9551).html
https://pure.amc.nl/en/publications/randomised-noninferiority-trial-1600-mg-versus-400-mg-tablets-of-mesalazine-for-the-treatment-of-mildtomoderate-ulcerative-colitis(f5d69f28-c590-4b69-be55-44a95d2c9551).html
Autor:
Christopher W Walker, Mark A. Valasek, Larry Stitt, Rish K. Pai, Reena Khanna, David K. Driman, Karel Geboes, Brian G. Feagan, William J. Sandborn, Robert H. Riddell, Mark A Samaan, Margaret K. Vandervoort, Sigrid Nelson, Mahmoud Mosli, Guangyong Zou, Valerie Frisbie, Barrett G. Levesque, Vipul Jairath, Geert D'Haens, Lisa M. Shackelton, Gregory Y. Lauwers
Publikováno v:
Gut, 66(1), 50-58. BMJ Publishing Group
Objective Although the Geboes score (GS) and modified Riley score (MRS) are commonly used to evaluate histological disease activity in UC, their operating properties are unknown. Accordingly, we developed an alternative instrument. Design Four pathol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f89c58c49bce3b9a9a80e63f76489c22
https://pure.amc.nl/en/publications/development-and-validation-of-a-histological-index-for-uc(ae4b72e0-1324-4195-9ffc-8a93094f7194).html
https://pure.amc.nl/en/publications/development-and-validation-of-a-histological-index-for-uc(ae4b72e0-1324-4195-9ffc-8a93094f7194).html
Autor:
Geert DʼHaens, Cynthia Behling, Brian G. Feagan, Margaret K. Vandervoort, Karel Geboes, Keith J. Kaplan, Barrett G. Levesque, David K. Driman, John K MacDonald, William J. Sandborn, Kenneth A. Baker, Lisa M. Shackelton, Mahmoud Mosli
Publikováno v:
Inflammatory Bowel Diseases. 20:564-575
BACKGROUND Ulcerative colitis (UC) is an idiopathic inflammatory disorder. Currently, the main goals of treatment are to induce and maintain clinical and/or endoscopic remission. However, evidence indicates that persistent disease activity on colonic
Autor:
George K. Dresser, Margaret K. Vandervoort, Jeffrey L. Mahon, Sigrid Nelson, Ross D. Feldman, Brian G. Feagan, Guangyong Zou, Cindy J. Wong
Publikováno v:
Journal of Hypertension. 31:1702-1713
Background Notwithstanding improving rates of hypertension control in North America, management of patients with both hypertension and dyslipidemia remains problematic. Based on evidence of improved control utilizing a simplified algorithm for manage
Autor:
Margaret K. Vandervoort, K. D. Grinwich, Donald H. Lee, H. Cauvier, B. J. Harris, S. J. Karlik, George P.A. Rice, Marybeth Hopkins, M. Penman, George C. Ebers, J. H. Noseworthy
We treated 13 patients with progressive MS with mitoxantrone. All patients received a standard IV dose of mitoxantrone (8 mg/m2) every 3 weeks for a total of seven infusions, with dosage adjustments depending on the hematologic profile at the nadir.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::900c88cf87d15ad15e1378bfe50abba8
https://doi.org/10.1212/wnl.43.7.1401
https://doi.org/10.1212/wnl.43.7.1401